Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study

L Gianni; CS Huang; D Egle; B Bermejo; C Zamagni; M Thill; A Anton; S Zambelli; G Bianchini; S Russo; E Ciruelos; Richard Greil; V Semiglazov; M Colleoni; C Kelly; G Mariani; L Del Mastro; I Maffeis; P Valagussa; G Viale

doi:10.1158/1538-7445.SABCS19-GS3-04

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study

L Gianni
, CS Huang
, D Egle
, B Bermejo
, C Zamagni
, M Thill
, A Anton
, S Zambelli
, G Bianchini
, S Russo
, E Ciruelos
, Richard Greil
, V Semiglazov
, M Colleoni
, C Kelly
, G Mariani
, L Del Mastro
, I Maffeis
, P Valagussa
, G Viale

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

117 Citations (Web of Science)

Original language	English
Journal	CANCER RESEARCH
Volume	80
Issue number	4
DOIs	https://doi.org/10.1158/1538-7445.SABCS19-GS3-04
Publication status	Published - 2020
Event	San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 10 Dec 2019 → 14 Dec 2019

Access to Document

10.1158/1538-7445.SABCS19-GS3-04

Cite this

Gianni, L., Huang, CS., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., Ciruelos, E., Greil, R., Semiglazov, V., Colleoni, M., Kelly, C., Mariani, G., Del Mastro, L., Maffeis, I., Valagussa, P., & Viale, G. (2020). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. CANCER RESEARCH , 80(4). https://doi.org/10.1158/1538-7445.SABCS19-GS3-04

Gianni, L ; Huang, CS ; Egle, D et al. / Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. In: CANCER RESEARCH 2020 ; Vol. 80, No. 4.

@article{5461aba569924e03ae379cf02ee96c05,

title = "Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study",

author = "L Gianni and CS Huang and D Egle and B Bermejo and C Zamagni and M Thill and A Anton and S Zambelli and G Bianchini and S Russo and E Ciruelos and Richard Greil and V Semiglazov and M Colleoni and C Kelly and G Mariani and \{Del Mastro\}, L and I Maffeis and P Valagussa and G Viale",

year = "2020",

doi = "10.1158/1538-7445.SABCS19-GS3-04",

language = "English",

volume = "80",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "4",

note = "San Antonio Breast Cancer Symposium ; Conference date: 10-12-2019 Through 14-12-2019",

}

Gianni, L, Huang, CS, Egle, D, Bermejo, B, Zamagni, C, Thill, M, Anton, A, Zambelli, S, Bianchini, G, Russo, S, Ciruelos, E, Greil, R, Semiglazov, V, Colleoni, M, Kelly, C, Mariani, G, Del Mastro, L, Maffeis, I, Valagussa, P & Viale, G 2020, 'Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study', CANCER RESEARCH , vol. 80, no. 4. https://doi.org/10.1158/1538-7445.SABCS19-GS3-04

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. / Gianni, L; Huang, CS; Egle, D et al.
In: CANCER RESEARCH , Vol. 80, No. 4, 2020.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study

AU - Gianni, L

AU - Huang, CS

AU - Egle, D

AU - Bermejo, B

AU - Zamagni, C

AU - Thill, M

AU - Anton, A

AU - Zambelli, S

AU - Bianchini, G

AU - Russo, S

AU - Ciruelos, E

AU - Greil, Richard

AU - Semiglazov, V

AU - Colleoni, M

AU - Kelly, C

AU - Mariani, G

AU - Del Mastro, L

AU - Maffeis, I

AU - Valagussa, P

AU - Viale, G

PY - 2020

Y1 - 2020

U2 - 10.1158/1538-7445.SABCS19-GS3-04

DO - 10.1158/1538-7445.SABCS19-GS3-04

M3 - Abstract (Journal)

SN - 0008-5472

VL - 80

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 4

T2 - San Antonio Breast Cancer Symposium

Y2 - 10 December 2019 through 14 December 2019

ER -

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. CANCER RESEARCH . 2020;80(4). doi: 10.1158/1538-7445.SABCS19-GS3-04